KB3305 - glucocorticoid antagonist

KB3305 is a first in class liver selective glucocorticoid antagonist for treatment of type 2 diabetes, and the first compound of its kind to be tested in man. In pre-clinical studies, KB3305 has been shown to be both efficacious and safe. Although Karo Bio has generated very positive proof-of-principle data from the clinical phase I program, in 2009, the company took the decision not to do further in-house development of KB3305 for the treatment of type 2 diabetes. The competitive situation within this field, the added requirements imposed by the FDA and internal resource prioritizations made the company come to this decision. Other potential therapy areas of use for the compound are being evaluated.